Evidence map›Paper›PMID 39896986›Full record

ArticleOpen forum infectious diseases2025

Defining Fulminant

Hubert C Chua, Taryn A Eubank, Allen Lee, Krishna Rao, Jinhee Jo, Kevin W Garey, Anne J Gonzales-Luna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Patients' Voice inOpen forum infectious diseases · 2026
    Article
  2. The Patients' Voice inmedRxiv : the preprint server for health sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hubert C ChuaDivision of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA.ORCID https://orcid.org/0009-0001-0999-7340
Taryn A EubankDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
Allen LeeDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-4861-7646
Krishna RaoDivision of Infectious Diseases, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-9213-7850
Jinhee JoDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
Kevin W GareyDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-2063-7503
Anne J Gonzales-LunaDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.

Funding

Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionR01AI139261 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Kevin W Garey, Julian G Hurdle · 2018 to 2026
$6.0M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
A Systems Biology Approach Using Fecal Microbiota and Metabolomics to Identify Novel Subtypes in Irritable Bowel Syndrome.K23DK124567 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEE, ALLEN A · 2021 to 2023
$729k
NIAID NIH HHS R01 AI139261NIAID NIH HHS T32 AI141349NIDDK NIH HHS K23 DK124567
6 · The paper itself

Abstract

Background: Fulminant Methods: This was a multicenter cohort study involving 1172 hospitalized patients diagnosed with Results: The composite endpoint was similar in the Houston cohort (98 patients [8.4%]) and the Midwest cohort (26 patients [5.3%]). Using either a MAP ≤65 mm Hg or SPB ≤90 mm Hg as criteria for hypotension was the best-performing model in both the development and validation cohorts. Removal of hypotension was the worst-performing model in both cohorts. Conclusions: Inclusion of hypotension, defined as SBP ≤90 mm Hg or MAP ≤65 mm Hg, was an important component of FCDI severity criteria, significantly improving the predictive ability to identify FCDI patients at risk for poor outcomes.

Indexed as

area under the receiver operating characteristic curveCDI severity criteriamean arterial pressuresystolic blood pressurevasopressor

Identifiers

PMID39896986
PMCPMC11783783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.